

## Behavioral Health and Substance Use Measure Evaluation Recusals

The [NQF CDP Conflict of Interest Policy](#) requires that Committee members identified as having a potential conflict of interest in relation to specific measures must recuse themselves from evaluation and voting on those measures when seated on the Committee.

In the review of disclosure of interests submitted by Committee members, NQF is requiring the following recusals be made during the measure evaluation period.

### Measures Under Review April 2018-January 2019 and Committee Member Recusals

Measure #	Measure Title	Measure Steward	Committee Member Recusals
0105	Antidepressant Medication Management (AMM)	National Committee for Quality Assurance (NCQA)	<p><b>Constance Horgan, ScD</b> Professor and Director, Institute for Behavioral Health, The Heller School for Social Policy and Management, Brandeis University</p> <p><b>Harold Pincus, MD</b> Director of Quality and Outcomes Research, New York-Presbyterian Hospital, The University Hospital of Columbia and Cornell</p>
1879	Adherence to Antipsychotic Medications for Individuals with Schizophrenia	Centers for Medicare and Medicaid Services (CMS)	<p><b>Constance Horgan, ScD</b> Professor and Director, Institute for Behavioral Health, The Heller School for Social Policy and Management, Brandeis University</p> <p><b>Harold Pincus, MD</b> Director of Quality and Outcomes Research, New York-Presbyterian Hospital, The University Hospital of Columbia and Cornell</p>

Measure #	Measure Title	Measure Steward	Committee Member Recusals
1880	Adherence to Mood Stabilizers for Individuals with Bipolar I Disorder	Centers for Medicare and Medicaid Services (CMS)	<p><b>Constance Horgan, ScD</b> Professor and Director, Institute for Behavioral Health, The Heller School for Social Policy and Management, Brandeis University</p> <p><b>Harold Pincus, MD</b> Director of Quality and Outcomes Research, New York-Presbyterian Hospital, The University Hospital of Columbia and Cornell</p>
1932	Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)	National Committee for Quality Assurance (NCQA)	<p><b>Constance Horgan, ScD</b> Professor and Director, Institute for Behavioral Health, The Heller School for Social Policy and Management, Brandeis University</p> <p><b>Harold Pincus, MD</b> Director of Quality and Outcomes Research, New York-Presbyterian Hospital, The University Hospital of Columbia and Cornell</p>
1933	Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (SMC)	National Committee for Quality Assurance (NCQA)	<p><b>Constance Horgan, ScD</b> Professor and Director, Institute for Behavioral Health, The Heller School for Social Policy and Management, Brandeis University</p> <p><b>Harold Pincus, MD</b> Director of Quality and Outcomes Research, New York-Presbyterian Hospital, The University Hospital of Columbia and Cornell</p>

Measure #	Measure Title	Measure Steward	Committee Member Recusals
1934	Diabetes Monitoring for People With Diabetes and Schizophrenia (SMD)	National Committee for Quality Assurance (NCQA)	<p><b>Constance Horgan, ScD</b> Professor and Director, Institute for Behavioral Health, The Heller School for Social Policy and Management, Brandeis University</p> <p><b>Harold Pincus, MD</b> Director of Quality and Outcomes Research, New York-Presbyterian Hospital, The University Hospital of Columbia and Cornell</p>
2152	Preventive Care and Screening: Unhealthy Alcohol Use: Screening & Brief Counseling	PCPI Foundation	<p><b>Peter Briss, MD, MPH</b> Medical Director, Centers for Disease Control and Prevention (CDC), National Center for Chronic Disease Prevention and Health Promotion</p>
3400	Use of pharmacotherapy for opioid use disorder (OUD)	Centers for Medicare & Medicaid Services, Centers for Medicaid & CHIP Services	<p><b>Constance Horgan, ScD</b> Professor and Director, Institute for Behavioral Health, The Heller School for Social Policy and Management, Brandeis University</p> <p><b>Mady Chalk, PhD, MSW</b> Principal, The Chalk Group</p>

### Related/Competing Measures and Committee Member Recusals

Measure #	Measure Title	Measure Steward	Committee Member Recusals
0541	Proportion of Days Covered (PDC): 3 Rates by Therapeutic Category	Pharmacy Quality Alliance (PQA)	<p><b>Constance Horgan, ScD</b> Professor and Director, Institute for Behavioral Health, The Heller School for Social Policy and Management, Brandeis University</p> <p><b>Harold Pincus, MD</b> Director of Quality and Outcomes Research, New York-Presbyterian Hospital, The University Hospital of Columbia and Cornell</p>

Measure #	Measure Title	Measure Steward	Committee Member Recusals
1661	SUB-1 Alcohol Use Screening	The Joint Commission	<b>Peter Briss, MD, MPH</b> Medical Director, Centers for Disease Control and Prevention (CDC), National Center for Chronic Disease Prevention and Health Promotion
1663	SUB-2 Alcohol Use Brief Intervention Provided or Offered and SUB-2a Alcohol Use Brief Intervention	The Joint Commission	<b>Peter Briss, MD, MPH</b> Medical Director, Centers for Disease Control and Prevention (CDC), National Center for Chronic Disease Prevention and Health Promotion
2599	Alcohol Screening and Follow-up for People with Serious Mental Illness	National Committee for Quality Assurance (NCQA)	<b>Constance Horgan, ScD</b> Professor and Director, Institute for Behavioral Health, The Heller School for Social Policy and Management, Brandeis University  <b>Harold Pincus, MD</b> Director of Quality and Outcomes, Research, New York-Presbyterian Hospital, The University Hospital of Columbia and Cornell  <b>Peter Briss, MD, MPH</b> Medical Director, Centers for Disease Control and Prevention (CDC), National Center for Chronic Disease Prevention and Health Promotion
3175	Continuity of Pharmacotherapy for Opioid Use Disorder	RAND Corporation	<b>Constance Horgan, ScD</b> Professor and Director, Institute for Behavioral Health, The Heller School for Social Policy and Management, Brandeis University  <b>Mady Chalk, PhD, MSW</b> Principal, The Chalk Group